指南与共识免疫规划传染病防控与疫情报告

共识流感血凝素序贯免疫可诱导针对多种异源HA株的交叉反应性中和抗体

Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains.
指南 / 共识 · Vaccine · 2016-11-30

研究设计跨亚型序贯免疫策略,用假病毒中和试验评估小鼠中和抗体活性。结果显示,与传统的疫苗策略相比,跨亚型序贯免疫可在小鼠中显著诱导广泛的血清交叉反应性中和抗体,对同源株亦有作用,并提供针对异源病毒PR8(H1N1)攻击的保护。从序贯免疫小鼠中分离的两株单克隆抗体对多种流感株具有强效广谱中和活性,提示序贯免疫用于通用流感疫苗开发的可行性。

要点

  • 跨亚型序贯免疫在小鼠中显著诱导广泛的血清交叉反应性中和抗体。
  • 序贯免疫提供针对异源病毒PR8(H1N1)攻击的保护。
  • 分离的两株单克隆抗体对多种流感株具有强效广谱中和活性。

核心结论

  • 跨亚型序贯免疫在小鼠中显著诱导广泛的血清交叉反应性中和抗体,并保护免受异源病毒PR8(H1N1)攻击,提示序贯免疫用于通用流感疫苗开发的可行性。

研究设计与样本

  • 研究设计跨亚型序贯免疫策略,并用假病毒中和试验评估小鼠中和抗体活性。

主要发现

  • 与传统的疫苗策略相比,跨亚型序贯免疫在小鼠中显著诱导广泛的血清交叉反应性中和抗体,对同源株亦有作用。
  • 序贯免疫提供针对异源病毒PR8(H1N1)攻击的保护。
  • 从序贯免疫小鼠中分离的两株单克隆抗体对多种流感株具有强效广谱中和活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Seasonal and emerging epidemics caused by influenza virus remain as a public health concern and an economic burden. The weak immunogenicity of conserved epitopes on hemagglutinin that induces broad protective immune responses is the main obstacle to the development of universal vaccines. In the present report, we designed the cross-subtypic sequential vaccination strategy and evaluated its neutralizing antibody (nAb) activity by pseudovirus-based neutralization assays. The results clearly indicated that compared with traditional vaccines strategy, the cross-subtypic sequential immunization could significantly induce a broad serum cross-reactive nAb response in mice as well as against homologous strains, and provide protection from heterologous virus PR8 (H1N1) challenge. Furthermore, we isolated two monoclonal antibodies from sequentially immunized mice, which had potent broadly neutralizing activity against multiple influenza strains. These data suggest the feasibility of sequential immunization in universal flu vaccine development.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhou H, Huang Y, Yuan S, et al. Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains. Vaccine. 2016. PMID: 27914743. doi:10.1016/j.vaccine.2016.11.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。